Multimodality approach for locally advanced esophageal cancer

Locally Advanced Esophageal Cancer

Preoperative therapy in locally advanced esophageal cancer

Esophageal cancer is an aggressive malignancy associated with dismal treatment outcomes. Presence of two distinct histopathological types distinguishes it from other gastrointestinal tract malignancies. Surgery is the cornerstone of treatment in locally advanced esophageal cancer (T2 or greater or node positive); however, a high rate of disease recurrence (systemic and loco-regional) and poor s...

Multimodality Therapy for Esophageal Cancer.

Adjuvant and neoadjuvant therapeutic principles have in recent years received increasing attention in the management of patients with esophageal cancer. A series of randomized prospective trials has convincingly demonstrated that adjuvant postoperative radiation or chemotherapy does not result in a survival advantage after a complete tumor resection. The available data on the role of neoadjuvan...

Multimodality therapy for esophageal cancer.

Recent developments in the epidemiology, staging, and treatment of esophageal and gastroesophageal junction cancers have led to significant changes in the way these malignancies are managed. Although a relationship between gastroesophageal reflux disease and esophageal cancer has been demonstrated, antireflux surgery has been shown to have no preventive effect with regard to the development of ...

Multimodality treatment in locally advanced non-small cell lung cancer.

Prognosis in patients with locally advanced non-small cell lung cancer (NSCLC) is poor (five year survival rate of 5% [1]). Radiotherapy (RT), chemotherapy (CT) and surgery (S), as single modality therapeutical approaches are unable to eradicate locoregional disease and to control systemic microscopic disease. Concurrent chemoradiation (CTRT) is at present time deemed to be the standard of care...